<DOC>
	<DOCNO>NCT01309802</DOCNO>
	<brief_summary>Treating patient Raynaud 's phenomenon chronic pain ulceration extremely challenge . Published report previous work support hypothesis symptomatic patient experience relief pain heal ulceration minimal adverse effect treat botulinum toxin type A ( Btx-A ) injections Raynaud 's phenomenon . The propose study first clinical trial prospective study design document whether 1 ) Btx-A injection relieve pain patient 's hand affect Raynaud 's disease well placebo within 28 day injection , 2 ) Btx-A injection relieve pain associated Raynaud 's disease longer 28 day , improve patient ' quality life . Through study intend determine effect inject Btx-A relieve chronic pain ulceration ischemic hand characterize patient treatment effective .</brief_summary>
	<brief_title>A Two-Part Study BOTOX® Therapy Ischemic Digits</brief_title>
	<detailed_description>PROJECT SUMMARY OVERVIEW : Treating patient Raynaud 's phenomenon chronic pain ulceration extremely challenge . Pharmacologic vasodilator surgical sympathectomy offer variable benefit . Case report , small retrospective outcome study , previous work document symptomatic patient treat botulinum toxin type A ( Btx-A ) injections Raynaud 's phenomenon demonstrate relief pain heal ulceration minimal adverse effect . We propose conduct first clinical trial prospective study document efficacy novel treatment modality . STUDY AIMS : The aim proposal 1 ) examine short-term efficacy Btx-A injection compare placebo treat pain associate digit ischemia due Raynaud 's disease , 2 ) describe long-term efficacy Btx-A injection treat pain associate digit ischemia due Raynaud 's disease measure patient satisfaction quality life change time . APPROACH : Two group patient enrol : Group 1 consist patient primary Raynaud 's disease ( n=20 ) Group 2 patient secondary Raynaud 's ( n=20 ) . Comparisons treatment ( Btx ) placebo ( saline ) occur first 28 day determine Btx-A 's short-term efficacy . Follow-up visit occur Days 7 28 . Post-assessment Day 28 mark begin longitudinal observational study patient outcome . Placebo longer use patient still suffer pain eligible additional Btx-A injection . Patients may receive 4 injection Btx-A 1-year study period pain ulceration recur . During study period participant follow collect data pain-free interval , ulcer healing , subsequent treatment choice , patient satisfaction , change quality life hand function . Group comparison make analyze result . Further stratification data analysis make enrollment number allow control additional demographic disease variable . Quality-adjusted life-years calculate help determine societal individual cost treatment . HYPOTHESIS : We hypothesize 1 ) Btx-A injection relieve ischemic pain associate Raynaud 's disease well placebo within 28 day injection , 2 ) Btx-A injection relieve ischemic pain associate Raynaud 's disease longer 28 day , improve patient ' quality life . Through study intend elucidate efficacy inject Btx-A relieve chronic pain ulceration ischemic hand characterize patient treatment effective . This data help u apply national funding become coordinate center multi-center clinical trial . The result research enormous potential impact million patient suffer Raynaud 's phenomenon .</detailed_description>
	<mesh_term>Raynaud Disease</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>age 1875 year diagnose Raynaud 's disease/phenomenon ischemia due peripheral artery disease vascular disease otherwise healthy individual uptodate tetanus immunization ability return/be available followup evaluation ability/willingness give informed consent HIV/AIDS positive otherwise immunocompromised history neuromuscular disease report allergy BOTOX® ; report allergy lidocaine local anesthetic agent ever receive botulinum toxin vaccine ultrasound angiogram showing digital ischemia due block vessel Raynaud 's disease history symptom significant medical problem last year ( i.e. , bradycardia , impair cardiovascular function , liver disease ) symptoms infection illness initial enrollment pregnant lactate woman unable unwilling maintain abstinence use contraception 28 day follow injection cognitive impairment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>botox</keyword>
	<keyword>raynaud 's</keyword>
	<keyword>botulinum toxin</keyword>
	<keyword>botulinum toxin A</keyword>
	<keyword>raynaud 's disease</keyword>
	<keyword>raynaud 's syndrome</keyword>
	<keyword>raynaud 's phenomenon</keyword>
	<keyword>ischemic digit</keyword>
	<keyword>ischemia</keyword>
	<keyword>botox treatment</keyword>
	<keyword>onabotulinum</keyword>
	<keyword>onabotulinum toxin</keyword>
	<keyword>onabotulinum toxin type A</keyword>
</DOC>